Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and ADC-based therapies, has received another milestone payment from Boehringer Ingelheim (BI) for progressing a second oncology drug candidate (BI 765049) into the clinic.   In this Phase 1 clinical trial, BI 765049, will be administered to patients with advanced solid tumors including colorectal cancer, gastric carcinoma, pancreatic carcinoma, non-small cell lung cancer, hepatocellular carcinom...